The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Bacteriophage Endolysins as a Novel Class of Antibacterial Agents
Abstract
Endolysins are double-stranded DNA bacteriophage-encoded peptidoglycan hydrolases produced in phage-infected bacterial cells toward the end of the lytic cycle. They reach the peptidoglycan through membrane lesions formed by holins and cleave it, thus, inducing lysis of the bacterial cell and enabling progeny virions to be released. Endolysins are also capable of degrading peptidoglycan when applied externally (as purified recombinant proteins) to the bacterial cell wall, which also results in a rapid lysis of the bacterial cell. The unique ability of endolysins to rapidly cleave peptidoglycan in a generally species-specific manner renders them promising potential antibacterial agents. Originally developed with a view to killing bacteria colonizing mucous membranes (with the first report published in 2001), endolysins also hold promise for the treatment of systemic infections. As potential antibacterials, endolysins possess several important features, for instance, a novel mode of action, a narrow antibacterial spectrum, activity against bacteria regardless of their antibiotic sensitivity, and a low probability of developing resistance. However, there is only one report directly comparing the activity of an endolysin with that of an antibiotic, and no general conclusions can be drawn regarding whether lysins are more effective than traditional antibiotics. The results of the first preclinical studies indicate that the most apparent potential problems associated with endolysin therapy (e.g., their immunogenicity, the release of proinflammatory components during bacteriolysis, or the development of resistance), in fact, may not seriously hinder their use. However, all data regarding the safety and therapeutic effectiveness of endolysins obtained from preclinical studies must be ultimately verified by clinical trials. This review discusses the prophylactic and therapeutic applications of endolysins, especially with respect to their potential use in human medicine. Additionally, we outline current knowledge regarding the structure and natural function of the enzymes in phage biology, including the most recent findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks
Kluytmans, J., van Belkum, A., & Verbrugh, H. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.3.505 · Cited by 2,595
Nasal Carriage as a Source of Staphylococcus aureus Bacteremia
von Eiff, C., Becker, K., Machka, K., Stammer, H., & Peters, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440102 · Cited by 1,984
Streptococcus pneumoniae colonisation: the key to pneumococcal disease
Bogaert, D., de Groot, R., & Hermans, P. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)00938-7 · Cited by 1,929 · cited 2×
“In view of the prevalence of mucosal colonization (60, 67), the requirement of the development of novel topical antibacterials becomes apparent.”
BackgroundAgents that increase the permeability of the outer membrane
Vaara, M. (1992) · Microbiological Reviews · doi:10.1128/mr.56.3.395-411.1992 · Cited by 1,879
Ecology of prokaryotic viruses
Weinbauer, M. G. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2003.08.001 · Cited by 1,771
Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.649-659.2001 · Cited by 1,566
Intranasal Mupirocin to Prevent Postoperative Staphylococcus aureus Infections
Perl, T. M., Cullen, J. J., Wenzel, R. P., Zimmerman, M. B., Pfaller, M. A., Sheppard, D., Twombley, J., French, P. P., & Herwaldt, L. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003069 · Cited by 799
A bacteriolytic agent that detects and kills Bacillus anthracis
Schuch, R., Nelson, D., & Fischetti, V. A. (2002) · Nature · doi:10.1038/nature01026 · Cited by 656
Nelson, D., Loomis, L., & Fischetti, V. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061038398 · Cited by 578
Bacteriophage endolysins — current state of research and applications
Loessner, M. J. (2005) · Current Opinion in Microbiology · doi:10.1016/j.mib.2005.06.002 · Cited by 537
Cited by
Banerjee, I., Pangule, R. C., & Kane, R. S. (2011) · Advanced Materials · doi:10.1002/adma.201001215 · Cited by 2,749
Antibiotic resistance and persistence—implications for human health and treatment perspectives
Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. (2020) · The EMBO Reports · doi:10.15252/embr.202051034 · Cited by 850
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance
Ghosh, C., Sarkar, P., Issa, R., & Haldar, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.12.010 · Cited by 661
A review of the recent advances in antimicrobial coatings for urinary catheters
Singha, P., Locklin, J., & Handa, H. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.070 · Cited by 448
Metadata
- Authors
- Borysowski, J., Weber-Dąbrowska, B., & Górski, A.
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 2006-04
- Volume
- 231
- Issue
- 4
- Pages
- 366-377
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W1864887623
- Cited by
- 338
- References
- 72
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacteriophage Endolysins as a Novel Class of Antibacterial Agents. https://app.cochat.ai/papers/10.1177/153537020623100402
- The paper
- Borysowski, J., Weber-Dąbrowska, B., & Górski, A. (2006). Bacteriophage Endolysins as a Novel Class of Antibacterial Agents. Experimental Biology and Medicine. https://doi.org/10.1177/153537020623100402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.